nShift: Growing Ecoms Urged to Stop “Leaving Money on the Table” in 2025
10.12.2024 17:01:00 CET | Business Wire | Press release
nShift releases five ways that deliveries can solve business problems
Small and medium-sized ecommerce businesses fear they are leaving money on the table by failing to optimize their processes, learn from data analytics and improve their customer experience. Experts at nShift are calling on growing and ambitious ecom companies to make 2025 the year they start using the delivery process to maximize revenue and solve business challenges.
Smaller ecommerce businesses are better placed than their larger competitors to respond quickly to shifting customer expectations. But many may be missing opportunities to spot these trends. One in five small businesses does not actively track ecommerce analytics.1
nShift, the global leader in delivery and experience management, has identified five ways that the delivery process can help grow revenue, boost loyalty and solve business problems:
- Increase conversions at checkout – some 70% of shoppers confess to abandoning online shopping carts.2 nShift data shows that offering a range of delivery options at checkout can boost conversions by 20%
- Lower delivery costs – last-mile deliveries make up 41% of logistics costs.3 Investing in multi-carrier capability makes it easier to compare costs between suppliers and automatically pick the cheapest carrier for a delivery
- Faster growth – the right shipping software makes it far easier to ship to customers abroad, enabling businesses to tap into global markets. 52% of customers are happy to buy goods sold outside their home countries.
- Higher repeat purchases – a positive delivery experience leaves people likely to come back for more. Sending relevant messages during the delivery process creates the chance to weave in product promotions
- Lower losses from returns–returns risk becoming the silent killer of profit in online retail. Running a digital returns process makes it easier to convert returns into exchanges
Carl Nilsson, VP at nShift said: “When it comes to deliveries, growing ecoms leave money on the table. By focusing on using their existing processes better, they have the potential to significantly grow revenue in 2025.
“The delivery experience is a crucial component of the customer experience. It is when they receive their first delivery that the customer decides whether the retailer has kept their promise. The right range of delivery options at checkout increases customer choice. A clear returns policy and regular communications between the brand and the customer during the delivery process helps build trust. By perfecting the delivery processes, brands, retailers and warehouses can win customers for life.”
nShift’s solutions reduce complexity in the delivery process, creating access to a network of over 1000 carriers. A range of customer-facing applications make it possible for growing ecommerce companies to operate an end-to-end delivery process from checkout to returns, all through one, reliable platform.
About nShift:
nShift’s delivery & experience management platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.
1https://upcity.com/experts/ecommerce-optimization-study/
2https://www.hotjar.com/blog/cart-abandonment-stats/
3https://www.capgemini.com/insights/expert-perspectives/navigating-the-complex-web-of-last-mile-deliveries/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210203909/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom